Danger signals in regulating the immune response to solid organ transplantation

Journal of Clinical Investigation

Volumn 127, Issue 7, 2017, Pages 2464-2472

  Todd, Jamie L ^a   Palmer, Scott M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; DAMAGE ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG;

ALLOGRAFT FIBROSIS; CELLULAR STRESS RESPONSE; FIBROSIS; GRAFT DYSFUNCTION; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; HISTOCOMPATIBILITY; IMMUNOLOGY;

ANIMALS; HUMANS; IMMUNITY, INNATE; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; TRANSPLANTATION IMMUNOLOGY;

EID: 85021742804     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI90594     Document Type: Review

References (106)

1. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation. 2008;86(7):889-894.
2. Thornley TB, et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol. 2006;176(3):1561-1570.
3. Chen L, et al. TLR engagement prevents transplantation tolerance. Am J Transplant. 2006;6(10):2282-2291.
4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
5. Wu H, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117(10):2847-2859.
6. Krüger B, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A. 2009;106(9):3390-3395.
7. Weber DJ, et al. The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation. Sci Transl Med. 2014;6(252):252ra124.
8. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333(6):333-336.
9. Cui Y, et al. Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. J Clin Invest. 2015;125(11):4255-4268.
10. Johnsson C, Tufveson G. Serum hyaluronan - a potential marker of cardiac allograft rejection? J Heart Lung Transplant. 2006;25(5):544-549.
11. Rao PN, et al. Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation. J Heart Lung Transplant. 1994;13(6):958-962.
12. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013;13(6):453-460.
13. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003;111(10):1571-1578.
14. Wu H, et al. Absence of MyD88 signaling induces donor-specific kidney allograft tolerance. J Am Soc Nephrol. 2012;23(10):1701-1716.
15. Tesar BM, Zhang J, Li Q, Goldstein DR. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor signal adaptor protein. Am J Transplant. 2004;4(9):1429-1439.
16. Palmer SM, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med. 2003;168(6):628-632.
17. Oetting WS, Guan W, Schladt DP, et al. Donor polymorphisms of TLR4 associated with graft failure in liver transplant recipients. Liver Transpl. 2012;18(12):1399-1405.
18. Kaczorowski DJ, et al. Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation. 2009;87(10):1455-1463.
19. Yang Z, et al. TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Invest. 2013;93(7):792-800.
20. Sharma AK, LaPar DJ, Stone ML, Zhao Y, Kron IL, Laubach VE. Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. Am J Transplant. 2013;13(9):2255-2267.
21. Huang Y, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant. 2007;7(4):799-808.
22. Duan L, et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab Invest. 2011;91(1):43-53.
23. Zou H, et al. HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs. Am J Transplant. 2014;14(8):1765-1777.
24. He L, et al. HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-κB/HPSE signaling to enhance latent TGF-β release from ECM. Am J Transl Res. 2016;8(5):1971-1984.
25. Saito T, et al. Distinct expression patterns of alveolar "alarmins" in subtypes of chronic lung allograft dysfunction. Am J Transplant. 2014;14(6):1425-1432.
26. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature. 2014;509(7500):310-317.
27. Vergani A, et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation. 2013;127(4):463-475.
28. Yoshida O, et al. CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejection. Transpl Immunol. 2015;32(2):76-83.
29. Interewicz B, Olszewski WL, Stanislawska J, Sikora M, Durlik M, Maksymowicz M. DNA released from rejecting organs is an indicator of the degree of graft cellular damage. Transplant Proc. 2005;37(1):98-101.
30. Ott U, Aschoff A, Fünfstück R, Jirikowski G, Wolf G. DNA fragmentation in acute and chronic rejection after renal transplantation. Transplant Proc. 2007;39(1):73-77.
31. Hu Q, Wood CR, Cimen S, Venkatachalam AB, Alwayn IP. Mitochondrial damage-associated molecular patterns (MTDs) are released during hepatic ischemia reperfusion and induce inflammatory responses. PLoS One. 2015;10(10):e0140105.
32. De Vlaminck I, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6(241):241ra77.
33. De Vlaminck I, et al. Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. 2015;112(43):13336-13341.
34. Gielis EM, et al. Cell-Free DNA: An Upcoming Biomarker in Transplantation. Am J Transplant. 2015;15(10):2541-2551.
35. Oka T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485(7397):251-255.
36. Cao H, et al. Circulatory mitochondrial DNA is a pro-inflammatory agent in maintenance hemodialysis patients. PLoS One. 2014;9(12):e113179.
37. Moliterno R, Valdivia L, Pan F, Duquesnoy RJ. Heat shock protein reactivity of lymphocytes isolated from heterotopic rat cardiac allografts. Transplantation. 1995;59(4):598-604.
38. Moliterno R, et al. Heat shock protein-induced T-lymphocyte propagation from endomyocardial biopsies in heart transplantation. J Heart Lung Transplant. 1995;14(2):329-337.
39. Trieb K, Grubeck-Loebenstein B, Eberl T, Margreiter R. T cells from rejected human kidney allografts respond to heat shock protein 72. Transpl Immunol. 1996;4(1):43-45.
40. O'Neill S, Ingman TG, Wigmore SJ, Harrison EM, Bellamy CO. Differential expression of heat shock proteins in healthy and diseased human renal allografts. Ann Transplant. 2013;18:550-557.
41. Maehana T, et al. Heat shock protein 90α is a potential serological biomarker of acute rejection after renal transplantation. PLoS One. 2016;11(9):e0162942.
42. Abe K, et al. Interstitial expression of heat shock protein 47 and alpha-smooth muscle actin in renal allograft failure. Nephrol Dial Transplant. 2000;15(4):529-535.
43. Shi J, Yang D, Cong X, Li Y, Yang X, Liu Y. Expression of HSPA12B in acute cardiac allograft rejection in rats. Pathol Res Pract. 2015;211(1):20-26.
44. Sarri S, Shaw SM, Gieschen-Krische MA, Archer L, Yonan N, Fildes JE. Myocardial heat shock protein 60 expression is upregulated following acute cardiac rejection. Transpl Immunol. 2009;21(3):140-142.
45. Schimke I, et al. Increased level of HSP27 but not of HSP72 in human heart allografts in relation to acute rejection. Transplantation. 2000;70(12):1694-1697.
46. Baba HA, et al. Possible relationship between heat shock protein 70, cardiac hemodynamics, and survival in the early period after heart transplantation. Transplantation. 1998;65(6):799-804.
47. Wood KL, et al. The role of heat shock protein 27 in bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29(7):786-791.
48. Rizzo M, et al. Increased expression of HDJ-2 (heat shock protein 40) and heat shock protein 70 in biopsy specimens of transplanted human lungs. J Heart Lung Transplant. 1998;17(3):241-249.
49. De Souza AI, Wait R, Mitchell AG, Banner NR, Dunn MJ, Rose ML. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res. 2005;97(2):192-198.
50. Flohé S, Speidel N, Flach R, Lange R, Erhard J, Schade FU. Expression of HSP 70 as a potential prognostic marker for acute rejection in human liver transplantation. Transpl Int. 1998;11(2):89-94.
51. Shields AM, Panayi GS, Corrigall VM. Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol. 2011;165(3):292-300.
52. Borges TJ, et al. Prolonged survival of allografts induced by mycobacterial Hsp70 is dependent on CD4+CD25+ regulatory T cells. PLoS One. 2010;5(12):e14264.
53. Luna E, et al. Treatment with encapsulated Hsp60 peptide (p277) prolongs skin graft survival in a murine model of minor antigen disparity. Scand J Immunol. 2007;66(1):62-70.
54. Kovalchin JT, Mendonca C, Wagh MS, Wang R, Chandawarkar RY. In vivo treatment of mice with heat shock protein, gp 96, improves survival of skin grafts with minor and major antigenic disparity. Transpl Immunol. 2006;15(3):179-185.
55. Shen H, et al. Haptoglobin activates innate immunity to enhance acute transplant rejection in mice. J Clin Invest. 2012;122(1):383-387.
56. Shen H, et al. Haptoglobin enhances cardiac transplant rejection. Circ Res. 2015;116(10):1670-1679.
57. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91(1):221-264.
58. Wang A, de la Motte C, Lauer M, Hascall V. Hyaluronan matrices in pathobiological processes. FEBS J. 2011;278(9):1412-1418.
59. Jiang D, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173-1179.
60. Campo GM, et al. The inhibition of hyaluronan degradation reduced pro-inflammatory cytokines in mouse synovial fibroblasts subjected to collagen-induced arthritis. J Cell Biochem. 2012;113(6):1852-1867.
61. Shimizu M, et al. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol. 2003;30(6):1164-1172.
62. Syrjälä SO, et al. Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat. J Heart Lung Transplant. 2010;29(9):1047-1057.
63. Wu GD, Wang H, Zhu H, He Y, Barr ML, Klein AS. Genetic modulation of CD44 expression by intragraft fibroblasts. J Biochem. 2008;144(5):571-580.
64. Todd JL, et al. Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. Am J Respir Crit Care Med. 2014;189(5):556-566.
65. Cui Y, et al. Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. J Clin Invest. 2015;125(11):4255-4268.
66. Xu D, et al. Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol. 2013;8(7):1611-1620.
67. Platt JL, Wrenshall LE, Johnson GB, Cascalho M. Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues. Adv Exp Med Biol. 2015;865:123-140.
68. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002;168(10):5233-5239.
69. Rienstra H, et al. Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats. PLoS One. 2010;5(2):e9095.
70. Katta K, et al. Renal heparan sulfate proteoglycans modulate fibroblast growth factor 2 signaling in experimental chronic transplant dysfunction. Am J Pathol. 2013;183(5):1571-1584.
71. Soulez M, et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ Res. 2012;110(1):94-104.
72. O'Riordan E, et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl. 2008;2(7-8):1025-1035.
73. Adepu S, et al. Incipient renal transplant dysfunction associates with tubular syndecan-1 expression and shedding. Am J Physiol Renal Physiol. 2015;309(2):F137-F145.
74. Doege C, Koch M, Heratizadeh A, Sótonyi P, Mengel M, Nashan B. Chronic allograft nephropathy in athymic nude rats after adoptive transfer of primed T lymphocytes. Transpl Int. 2005;18(8):981-991.
75. Päiväniemi OE, Maasilta PK, Alho HS, Vainikka TL, Salminen US. Epithelial tenascin predicts obliterative airway disease. J Heart Lung Transplant. 2008;27(4):400-407.
76. Franz M, et al. Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol. 2010;134(5):503-517.
77. Nishioka T, et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2010;298(3):H1072-H1078.
78. Maqbool A, et al. Tenascin C upregulates interleukin-6 expression in human cardiac myofibroblasts via toll-like receptor 4. World J Cardiol. 2016;8(5):340-350.
79. Ruhmann M, Piccinini AM, Kong PL, Midwood KS. Endogenous activation of adaptive immunity: tenascin-C drives interleukin-17 synthesis in murine arthritic joint disease. Arthritis Rheum. 2012;64(7):2179-2190.
80. Okamura Y, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276(13):10229-10233.
81. Tanaka M, et al. A novel monitoring of kidney allograft rejection with plasma EDA(+) fibronectin. Transplant Proc. 1999;31(1-2):310-311.
82. Wieczorek G, et al. Acute and chronic vascular rejection in nonhuman primate kidney transplantation. Am J Transplant. 2006;6(6):1285-1296.
83. Franz M, et al. Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection. J Heart Lung Transplant. 2011;30(1):86-94.
84. Coito AJ, Kato H, Azimi R, Kupiec-Weglinski JW. Chronic allograft rejection versus tolerance: a critical role for EIIIA(+) fibronectin. Transplant Proc. 2001;33(1-2):526-527.
85. Booth AJ, et al. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol. 2012;226(4):609-618.
86. Franz M, et al. Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol. 2010;134(5):503-517.
87. Franz M, et al. De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection. J Mol Histol. 2014;45(5):519-532.
88. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem. 2014;289(51):35237-35245.
89. Land WG. The role of damage-associated molecular patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ Med J. 2015;15(2):e157-e170.
90. Land WG. The role of damage-associated molecular patterns in human diseases: part I - promoting inflammation and immunity. Sultan Qaboos Univ Med J. 2015;15(1):e9-e21.
91. Schaefer L. Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol. 2011;22(7):1200-1207.
92. Chen C, et al. Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury. J Am Heart Assoc. 2014;3(1):e000683.
93. Piccinini AM, Zuliani-Alvarez L, Lim JM, Midwood KS. Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages. Sci Signal. 2016;9(443):ra86.
94. Serini G, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol. 1998;142(3):873-881.
95. Webber J, Meran S, Steadman R, Phillips A. Hyaluronan orchestrates transforming growth factor-β1-dependent maintenance of myofibroblast phenotype. J Biol Chem. 2009;284(14):9083-9092.
96. Yusen RD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016;35(10):1170-1184.
97. Cypel M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431-1440.
98. Machuca TN, Cypel M, Bonato R, et al. Safety efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model [published online ahead of print January 4, 2017]. Hum Gene Ther. https://doi.org/10.1089/hum.2016.070.
99. Yeung JC, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther. 2012;20(6):1204-1211.
100. Wu H, et al. Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int. 2014;85(4):824-832.
101. Izuishi K, et al. Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol. 2006;176(12):7154-7158.
102. Seemampillai B, Germack R, Felkin LE, McCormack A, Rose ML. Heat shock protein-27 delays acute rejection after cardiac transplantation: an experimental model. Transplantation. 2014;98(1):29-38.
103. Netea MG, Latz E, Mills KH, O'Neill LA. Innate immune memory: a paradigm shift in understanding host defense. Nat Immunol. 2015;16(7):675-679.
104. Kashiwadate T, et al. Soluble thrombomodulin ameliorates ischemia-reperfusion injury of liver grafts by modulating the proinflammatory role of high-mobility group box 1. Tohoku J Exp Med. 2016;239(4):315-323.
105. Colombaro V, et al. Inhibition of hyaluronan is protective against renal ischaemia-reperfusion injury. Nephrol Dial Transplant. 2013;28(10):2484-2493.
106. Chong AS, Alegre ML. The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol. 2012;12(6):459-471.